8月21日，映恩生物-B盘中上涨5.22%，报197.5港元/股，成交额4669.57万港元。
消息面上，瑞银近日首次覆盖映恩生物-B，给予"买入"评级，目标价320港元，较当前股价存在约62%的上行空间。瑞银指出公司现价仅对应0.7倍风险调整后峰值销售比率，远低于同业中位数的1.6倍，估值具备吸引力；预计核心管线DB-1311峰值销售达383亿元人民币，高于市场共识的286亿元。此外，招商证券、东吴证券、中国银河证券此前亦先后首次覆盖并给予积极评级。同时，公司将于8月28日披露中期业绩，叠加此前持续回购动作，机构看多情绪与业绩释放预期形成共振。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.